Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

We have observed 21 EP applications Mark Hillier has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after September 19, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12706858

QUINOLINONE DERIVATIVES

IPC classification:
A61K 31/4709, A61K 31/47, C07D 417/14, C07D 417/10, C07D 417/04, C07D 413/14, C07D 413/04, C07D 409/14, C07D 401/14, C07D 401/10, C07D 401/04, C07D 215/36, C07D 215/20, A61P 25/28, A61P 25/16, A61P 9/10, A61P 3/10
Applicant:
GlaxoSmithKline LLC
Agent:
Mark Hillier, GlaxoSmithKline
Status:
GRANT OF PATENT INTENDED
EP12738141

HETEROCYCLYL PYRIMIDINE ANALOGUES AS JAK INHIBITORS

IPC classification:
A61K 31/505, C07D 491/10, C07D 403/12, A61P 35/00
Applicant:
Cellzome Ltd
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12762577

PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS KINASE INHIBITORS

IPC classification:
A61K 31/519, C07D 487/04, C07D 471/04, A61P 37/06
Applicant:
Cellzome Ltd
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12800913

TRPV4 ANTAGONISTS

IPC classification:
A61K 31/422, C07D 413/14, C07D 413/08, A61P 9/04
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12814591

TRPV4 ANTAGONISTS

IPC classification:
C07D 498/00, C07D 419/14, C07D 263/52
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12806057

PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS

IPC classification:
A61K 31/506, C07D 403/14, A61P 37/00, A61P 35/00
Applicant:
Cellzome Ltd
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12797080

NOVEL COMPOUNDS

IPC classification:
A61K 31/437, A01N 43/42, C07D 519/00, C07D 471/04, C07D 401/00, A61P 25/28
Applicant:
GlaxoSmithKline Intellectual Property Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13738099

THERAPEUTIC USES

IPC classification:
A61K 31/55, A61K 31/501, A61K 31/4545, A61K 31/445, A61K 31/4245, A61K 31/4174, C07D 401/12, C07D 317/48, C07D 237/14, C07D 233/64, C07D 223/16, C07D 211/14, A61P 25/00
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12801296

TRPV4 ANTAGONISTS

IPC classification:
A61K 31/423, C07D 413/08, A61P 9/10
Applicant:
GlaxoSmithkline Intellectual Property (No. 2) Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
PATENT GRANTED
EP12706859

1H-PYROLLO[3,2-d]PYRIMIDINEDIONE DERIVATIVES

IPC classification:
A61K 31/519, C07D 487/04, A61P 35/00, A61P 9/00, A61P 3/00
Applicant:
GlaxoSmithKline LLC
Agent:
Mark Hillier, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13724816

HETEROCYCLYL PYRIMIDINE ANALOGUES AS TYK2 INHIBITORS

IPC classification:
A61K 31/505, C07D 413/14, C07D 405/14, C07D 403/12, C07D 401/14, A61P 37/00
Applicant:
Cellzome Ltd
Agent:
Mark Hillier, GlaxoSmithKline
Status:
The patent has been granted
EP15166109

PYRIDINYL- AND PYRAZINYL -METHYLOXY - ARYL DERIVATIVES USEFUL AS INHIBITORS OF SPLEEN TYROSINE KINASE (SYK)

IPC classification:
A61K 31/47, C07D 403/12, C07D 401/12, A61P 37/00
Applicant:
Glaxo Group Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
The patent has been granted
EP14818951

3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL)PROPANOIC ACID DERIVATIVES AS KMO INHIBITORS

IPC classification:
A61P 25/00, A61K 31/501, A61K 31/506, A61K 31/4439, A61K 31/423, C07D 413/12, C07D 263/58
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
The patent has been granted
EP15743797

COMPOUNDS

IPC classification:
A61P 25/16, A61K 31/519, C07D 487/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15743645

COMPOUNDS

IPC classification:
A61P 25/16, A61K 31/4375, A61K 31/437, C07D 403/02, C07D 403/00, C07D 487/00, C07D 487/04
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15720312

A PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE

IPC classification:
A61P 25/28, A61K 31/4025, C07D 405/14
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
EXAMINATION REQUESTED
EP15810681

3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOIC ACID USEFUL AS KYNURENINE MONOOXYGENASE INHIBITORS

IPC classification:
A61P 1/00, A61P 31/00, A61P 25/00, A61K 31/506, A61K 31/501, A61K 31/4439, A61K 31/423, C07D 413/12
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
Request for examination was made
EP16723363

3-(6-CHLORO-3-OXO-3,4-DIHYDRO-(2H)-1,4-BENZOXAZIN-4-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS

IPC classification:
A61P 31/00, A61P 29/00, A61P 25/00, A61P 13/12, A61P 11/00, A61P 1/18, A61P 1/16, A61K 31/538, C07D 413/12
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
Request for examination was made
EP16723364

3-(5-CHLORO-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-3-YL) PROPANOIC ACID DERIVATIVES AND THEIR USE AS KMO INHIBITORS

IPC classification:
A61P 31/00, A61P 29/00, A61P 25/00, A61P 13/12, A61P 11/00, A61P 1/18, A61P 1/16, A61K 31/506, A61K 31/501, A61K 31/4439, C07D 417/12
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
Request for examination was made
EP16745509

TREATMENT FOR VITILIGO

IPC classification:
A61P 17/00, A61K 31/55, A61K 31/4725, A61K 31/472, A61K 31/4439, A61K 31/00
Applicant:
Glaxo Group Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
Request for examination was made
EP16823162

D-PROLINE DERIVATIVES AS SAP DEPLETING AGENT

IPC classification:
A61P 25/28, A61K 31/4025, C07D 405/14
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Mark Hillier, GlaxoSmithKline
Status:
Request for examination was made

Please Sign in to use this feature